Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Glenmark Life Sciences — Q3 FY24 Earnings Presentation
20 slides from Alivus Life Sciences's earnings presentation, Jan 23, 2024
Slide 1: Stock exchange cover letter for investor presentation
January 23, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q3 FY24
Investor Presentation Q3 FY24
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q3 FY24 | Highlights
Q3 FY24 | Highlights “Our Q3 FY24 numbers reflect our commitment to quality growth, with revenue from operations rising by 5.9%. This was fuelled by the robust performance of the US, Dr. Yasir Rawjee LATAM, RoW and India (ex-GPL) markets. Our external business continued its upward Managing Director
Slide 5: Q3 & 9M FY24 Performance
Q3 & 9M FY24 Performance Strong growth with stable margins PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) PAT Margin (In ₹) EBITDA Margin 5.9% 23.6% 23.4% 33.7% 33.7% 19.4% 19.9% 20.7% 29.0% 30.4% 1,464 28.1% 11.94 6,213 1,355 11.05 2,093 1,187 1,950 9.69
Slide 6: P&L Highlights | Q3 & 9M FY24
P&L Highlights | Q3 & 9M FY24 Particulars (In ₹ Millions) Q3 FY24 Q2 FY24 QoQ Q3 FY23 YoY 9M FY24 9M FY23 YoY Revenue from Operations 5,728 5,954 -3.8% 5,407 5.9% 17,466 15,399 13.4% Gross Profit 3,306 3,223 2.6% 2,759 19.8% 9,833 8,062 22.0% Gross Profit (%) 57.7% 54.1% 51.0% 56.3% 52.4% Other Inco
Slide 7: Strong Returns Indicators
Strong Returns Indicators ROICE Fixed Assets Turnover Working Capital Days 40% 202 36% 171 170 34% 35% 3.3 3.4 176 152 31% 2.9 2.9 98 102 103 99 89 152 136 122 120 116 FY20 FY21 FY22 FY23 9M FY24 -48 -43 -53 FY20 FY21 FY22 FY23 9M FY24 -67 -55 • ROICE is tracking at ~35% – Higher capital employed dr
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 31.0% 20.4% 19.7% 31.5% 31.4% CAGR 11.4% 29.7% 20.8% 18.6% 21,612 21,232 38.1
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance | Generic & CDMO business
Segment Performance | Generic & CDMO business Generic API CDMO (Rev enu e In ₹ Milli o n s) (Rev enu e In ₹ Milli o n s ) 568 5,428 464 5,299 5,105 5,042 279 253 4,799 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 • CDMO business witnessed a strong growth of • Gener
Slide 11: Segment Performance | GPL vs. External
Segment Performance | GPL vs. External External GPL GPL External (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 37.2% 33.9% 33.5% 73.1% 29.0% 2,309 26.9% 71.0% 1,964 2,000 66.5% 66.1% 1,594 62.8% 3,954 3,814 3,904 3,821 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q3 FY23 Q4
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 18% 19% 22% 20% 19% 34% 32% 31% 39% 39% 5% 6% Others 6% 3% 5% Emerging 5% 6% 4% Pain Management Markets 3% 4% 17% 15% 12% 18% Diabetes 82% 81% 78% 80% 81% 15% Regulated CNS Markets CVS 40% 43% 43% 36% 38% Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24
Slide 13: Company Overview
Company Overview LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint • Filed 502 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 97 126 160 10+ 18 125+ 10+ 50+ 22 79 (Brazil) India – Mix of Regulated Number of Number of customers As of Dec 31, 2023 Reg
Slide 15: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Milli o n s) North Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 37 31 4 21 10 34 137 As % to Sales CNS 37 22 8 13 2 16 98 Diabetes 10 5 - 8 - 12 35 3.2% 3.0% Pain Management 1 2 - 4 1 8 16 Others 75 37 6 33 9 56 216 2
Slide 16: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Last USFDA Mahape, Navi Mumbai Location Annual Installed Capacity Approvals Inspection Date R&D for new product development and complex USFDA, MHRA (UK), FIMEA (Finland), molecules High-
Slide 17: Strategy Going Forward
Strategy Going Forward / LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion Focus on new markets becoming more regulated New Growth levers 2 Pursue 2nd source opportunities with top generic players Ramp up CDMO portfolio Expand into complex API platforms Iron compounds Onco
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Status & Planned Capacity Timelines 208 KL (Under Construction) Q4 FY24 Brownfield API / Intermediate Ankleshwar Planned addition of 280KL-300KL FY25-FY26 Brownfield API Dahej Planned addition of 220KL-240KL FY25-FY26 CTE re
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RAHUL THAKUR Email: Diwakar.Pingle@in.ey.com Email: Rahul.Thakur@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 4th Floor, OIA House, 47
Glenmark Life Sciences — Q3 FY24 Earnings Presentation on 6ix